ATE204176T1 - Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven - Google Patents

Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven

Info

Publication number
ATE204176T1
ATE204176T1 AT92924246T AT92924246T ATE204176T1 AT E204176 T1 ATE204176 T1 AT E204176T1 AT 92924246 T AT92924246 T AT 92924246T AT 92924246 T AT92924246 T AT 92924246T AT E204176 T1 ATE204176 T1 AT E204176T1
Authority
AT
Austria
Prior art keywords
analogues
insulin
treatment
growth factors
optic nerve
Prior art date
Application number
AT92924246T
Other languages
English (en)
Inventor
Donna Bozyczko-Coyne
Nicola Neff
Michael E Lewis
Mohamed Iqbal
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Application granted granted Critical
Publication of ATE204176T1 publication Critical patent/ATE204176T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
    • A01N57/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-carbon bonds
    • A01N57/20—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-carbon bonds containing acyclic or cycloaliphatic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3813—N-Phosphonomethylglycine; Salts or complexes thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92924246T 1991-11-08 1992-11-03 Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven ATE204176T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79069091A 1991-11-08 1991-11-08
US07/963,329 US6310040B1 (en) 1991-11-08 1992-10-15 Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
PCT/US1992/009443 WO1993008826A1 (en) 1991-11-08 1992-11-03 Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs

Publications (1)

Publication Number Publication Date
ATE204176T1 true ATE204176T1 (de) 2001-09-15

Family

ID=27121062

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92924246T ATE204176T1 (de) 1991-11-08 1992-11-03 Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven

Country Status (9)

Country Link
US (1) US6310040B1 (de)
EP (1) EP0670729B1 (de)
JP (1) JP3445269B2 (de)
AT (1) ATE204176T1 (de)
CA (1) CA2122340C (de)
DE (1) DE69232008T2 (de)
DK (1) DK0670729T3 (de)
ES (1) ES2160581T3 (de)
WO (1) WO1993008826A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
EP0729361A4 (de) * 1993-11-15 1996-11-06 Celtrix Pharma Verfahren zur behandlung neurologischer erkrankungen
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
AU3545795A (en) * 1994-09-08 1996-03-27 Chiron Corporation A method of improved production of insulin-like growth factor
JP3191038B2 (ja) 1996-06-26 2001-07-23 輝夫 西田 眼科用医薬組成物
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
EP1005869A4 (de) * 1997-03-24 2004-06-23 Fujisawa Pharmaceutical Co Gallensekretion fördernde verbindungen
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
JP3971108B2 (ja) 1999-01-06 2007-09-05 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ突然変異体
AU3737500A (en) * 1999-03-12 2000-09-28 Genentech Inc. Method of preventing the death of retinal neurons and treating ocular diseases
AU6391000A (en) * 1999-07-28 2001-02-19 Genentech Inc. Method of preventing the injury or death of retinal cells and treating ocular diseases
GB9928323D0 (en) * 1999-11-30 2000-01-26 Cyclacel Ltd Peptides
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
DE60133271T2 (de) 2000-05-16 2009-04-23 Genentech, Inc., South San Francisco Behandlung von knorpelerkrankungen
DE60107416T2 (de) * 2000-05-31 2005-12-01 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion
DK1772464T3 (da) 2001-02-09 2009-12-14 Genentech Inc Fremgangsmåder til identificering af indirekte agonister af IGF-1
DE60232880D1 (de) 2001-05-24 2009-08-20 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
JP4253743B2 (ja) * 2001-12-03 2009-04-15 輝夫 西田 新規ペプチドおよびその医薬用途
TWI305778B (en) * 2001-12-03 2009-02-01 Nishida Teruo Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use
WO2006076342A2 (en) * 2005-01-11 2006-07-20 Heart Failure Technologies, Inc. Method and system for treating heart failure
JP2008538501A (ja) * 2005-04-20 2008-10-30 オークランド ユニサービシーズ リミティド ベシキュリン
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
EP1989226A4 (de) * 2006-03-06 2009-11-18 Caregen Co Ltd Peptide mit insulin like growth factor-1-aktivitäten und anwendungen davon
WO2009070650A1 (en) * 2007-11-26 2009-06-04 The Research Foundation Of State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
AU2009244148B2 (en) * 2008-05-07 2014-10-09 Biomarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
EP4219708A3 (de) 2009-07-17 2023-10-11 Aaron Thomas Tabor Zusammensetzungen und verfahren zur genetischen modifikation von zellen mit kosmetischer funktion zur verbesserung des kosmetischen erscheinungsbildes
WO2011011073A1 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1
KR101417872B1 (ko) 2009-07-22 2014-07-09 입센 파마 에스.에이.에스 59번 위치에 아미노산 치환을 포함하는 인슐린 유사 성장 인자-1(ｉｇｆ-1)의 유사체
TWI490371B (zh) 2009-07-28 2015-07-01 Industrie De Nora Spa 電解應用上的電極及其製法以及在電極表面上陽極釋氧之電解法和電冶法
AU2010328186B2 (en) 2009-12-08 2014-12-18 Case Western Reserve University Compounds and methods of treating ocular disorders
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
CN111763680A (zh) * 2019-05-22 2020-10-13 杭州杰迪生物科技有限公司 一种人胰岛素样生长因子-i或其类似物的制备方法、编码基因、表达载体及宿主细胞

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598205B2 (en) * 1985-08-22 1990-06-21 Gropep Pty Ltd Peptide analogues of mammalian insulin-like growth factor-1
US4783524A (en) 1985-09-17 1988-11-08 Monsanto Company Growth factors
SE8505920D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab New protein and its use
DE3851776T2 (de) 1987-04-28 1995-05-04 Boehringer Mannheim Gmbh Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
JP2507106B2 (ja) 1987-12-24 1996-06-12 グロペップ プロプライエタリー リミテッド インスリン様成長因子１（ｉｇｆ―１）または因子２（ｉｇｆ―２）の類縁ペプチド
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
ES2101865T3 (es) * 1991-08-01 1997-07-16 Genentech Inc Igf-1 para mejorar el estado neural.
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs

Also Published As

Publication number Publication date
EP0670729B1 (de) 2001-08-16
DK0670729T3 (da) 2001-12-10
ES2160581T3 (es) 2001-11-16
DE69232008D1 (de) 2001-09-20
DE69232008T2 (de) 2001-11-29
CA2122340C (en) 2007-06-12
EP0670729A4 (de) 1995-05-10
WO1993008826A1 (en) 1993-05-13
JP3445269B2 (ja) 2003-09-08
JPH07500839A (ja) 1995-01-26
US6310040B1 (en) 2001-10-30
CA2122340A1 (en) 1993-05-13
EP0670729A1 (de) 1995-09-13

Similar Documents

Publication Publication Date Title
ATE204176T1 (de) Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven
CA2058443A1 (en) Treating Disorders by Application of Insulin-Like Growth Factors and Analogs
SE8703625D0 (sv) New medical use
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
ATE94069T1 (de) Verwendung von physiologisch wirksamen substanzen zur herstellung von medikamenten fuer gehirn- und nervenerkrankungen.
ATE390932T1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69203596D1 (de) Biologisch abbaubare und biologisch absorbierbare führungskanäle zur verwendung in der behandlung und regenerierung von nerven.
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
DE3865368D1 (de) Thiophensulfonamide zur behandlung von glaukom.
ATE220923T1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
ATE78397T1 (de) Verwendung von p-chlorophenoxyazetat von n,ndimethylbiguanidzur behandlung von neuropathien und nervendegeneration.
ATE108658T1 (de) Verwendung von tetracycline zur herstellung eines arzneimittels zum herabsetzen des augendrucks.
US6174541B1 (en) Skin aging and wound treatment using cell migration agents
EP0515434A4 (en) Method for treating intestinal diseases
NO933742L (no) Humant, benavledet, insulinlignende vekstfaktorbindingsprotein
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69124382T3 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
DE69836689D1 (de) Verwendung von Amylin, Adrenomedullin und deren Analoga zur Behandlung von Knorpeldefekten
DE3877102D1 (de) Methode fuer die behandlung von viraler gehirnentzuendung.
AU7931487A (en) Therapeutic treatment of abnormal cell growth with follicle regulatory protein
RU93010715A (ru) Способ лечения прогрессирующей близорукости